News

Company News & Events

Oryzon receives approval to begin REIMAGINE: a Phase IIa clinical trial with Vafidemstat (ORY-2001) in aggressiveness

7 September 2018

MADRID, SPAIN and CAMBRIDGE MA.

• The approval has been granted by the Spanish Medicines Agency

• The study will be done in patients with 3 psychiatric disorders and 2 neurodegenerative disorders

• This is the first Phase IIa study with Vafidemstat (ORY-2001) in the psychiatric field

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today the approval by the Spanish Medicines Agency (AEMPS) of a clinical trial authorization (CTA) to carry out a Phase IIa trial with Vafidemstat (ORY-2001) in patients with episodes of aggressiveness.

 

Click here to see the full Press Release

 

Posted In: 
News
Investors

Share this story